|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on these observations and the established central role of chloride in the renin-angiotensin-aldosterone system, I propose a unifying hypothesis of the "chloride theory" for HF pathophysiology, which states that changes in the serum chloride concentration are the primary determinant of changes in plasma volume and the renin-angiotensin-aldosterone system under worsening HF and therapeutic resolution of worsening HF.
|
28673579 |
2017 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with kidney disease, particularly in those in whom diabetes and heart failure are present or are on treatment with renin-angiotensin-aldosterone system inhibitors (RAASIs).
|
31119681 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fear of this often asymptomatic finding limits enthusiasm for recommending potassium intake and often limits the use of renin-angiotensin-aldosterone system blockers in patients with heart failure and chronic kidney diseases.
|
29029808 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic treatment of hypertension or heart failure very often includes an angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) as renin-angiotensin system inhibitors (RASi) treatments.
|
30836981 |
2019 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study.
|
31493202 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Search inclusion criteria included studies describing either the incidence of HK events and any associated risk factors, or associations between HK or serum potassium concentration and adverse clinical outcomes including mortality, hospitalisation, major adverse cardiac events (MACE) and renin-angiotensin-aldosterone system inhibitors (RAASi) discontinuation in adult patients with chronic kidney disease (CKD), heart failure (HF), type 2 diabetes (T2DM) or hypertension.
|
31532067 |
2020 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recurrent hyperkalemia frequently limits use of renin-angiotensin-aldosterone system inhibitors (RAASi) in chronic kidney disease (CKD) patients with hypertension, diabetes, and/or heart failure.
|
28129247 |
2017 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy.
|
28875746 |
2018 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Heart failure oral therapies (HFOTs), including beta-blockers (BB), renin-angiotensin system inhibitors (RASi) and mineralocorticoid receptor antagonists, administered before hospital discharge after acute heart failure (AHF) might improve outcome.
|
28849606 |
2018 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of PDE9 had a negligible effect on circulating hormones at the lower doses, but post-high dose, acutely increased renin activity (Normal: p < 0.001; HF: p < 0.05), vasopressin (Normal: p < 0.001; HF: p < 0.01), and cyclic adenosine monophosphate (HF: p < 0.001).
|
31416533 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
CTD_human |
Captopril therapy for severe CHF: hypotensive response in presence of markedly elevated PRA.
|
7034517 |
1982 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results of this study provide a rationale for pharmacological therapies or posttranslational regulation therapies targeting genes expressed differentially in the renin-angiotensin system to remedy structural remodeling associated with atrial enlargement and heart failure progression in patients with MR.
|
30581499 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The renin-angiotensin system promotes oxidative stress, apoptosis, necrosis, fibrosis, and thus heart failure.
|
30247805 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The renin-angiotensin system (RAS), which plays an important role in the progression of heart failure, is efficiently blocked by the inhibition of renin, the rate-limiting enzyme in the RAS cascade.
|
30092100 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
While targeting the renin-angiotensin-aldosterone system is currently used as the standard line of therapy for heart failure, there has been increased interest in inhibiting the transforming growth factor-β signaling pathway due its established role in cardiac fibrosis.
|
30930180 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Renin-angiotensin aldosterone system (RAAS) inhibitors significantly improve outcome in heart failure (HF) patients with reduced ejection fraction (HFREF), irrespective of the occurrence of worsening renal function (WRF).
|
28209765 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
It has been previously documented that overactivation of the renin angiotensin system (RAS) is involved in HF pathophysiological mechanism.
|
31629013 |
2019 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, the efficacy of medical treatment for heart failure (HF) including renin-angiotensin inhibitors and β-blockers has not been defined in TRC.
|
30859381 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, although some conventional therapies, such as renin-angiotensin-aldosterone system (RAAS) inhibitors, have been shown to reduce cardiac fibrosis in humans, cardiac fibrosis persists in patients with heart failure even when treated with these conventional therapies, indicating a need to develop novel and effective anti-fibrotic therapies in cardiovascular disease.
|
28428753 |
2017 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In summary, in HF, the increases in renal norepinephrine spillover and plasma renin activity are augmented compared with the increase in RSNA.
|
31241978 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Indeed, the development of hypertension as well as the progression of coronary artery disease and heart failure have two factors in common: (1) display distinct gender specific characteristics and (2) are enhanced by the renin-angiotensin system.
|
11861038 |
2002 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Renin-angiotensin-aldosterone system inhibitors (RAASi) are now a standard treatment in most patients with cardiovascular disease, especially in those with heart failure (HF).
|
31800079 |
2019 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hyperkalemia (HK) occurs often among patients with chronic kidney disease (CKD) and heart failure (HF) and those treated with renin-angiotensin-aldosterone system inhibitors (RAASI).
|
29667438 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hearts from hypertensive homozygous renin-overexpressing (Ren-2) rats that had progressed to early HF were compared by microarray analysis to Ren-2 rats that had remained compensated.
|
15284191 |
2004 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effect of dual renin-angiotensin system (RAS) inhibition in heart failure (HF) is still controversial.
|
31814505 |
2020 |